Board of Directors

, Dr. , Calvin R. Stiller , , Chair

Dr. Calvin R. Stiller of London, Ontario is a Member of the Order of Ontario and Officer of the Order of Canada, was the recipient of the Canada Gairdner Wightman Award in 2011 (awarded to a Canadian who has demonstrated outstanding leadership in medicine and medical science) and was inducted into the Canadian Medical Hall of Fame in 2010. Dr. Stiller is Chair Emeritus of the Ontario Institute for Cancer Research, the former chair of Genome Canada and is Professor Emeritus in the Department of Medicine at the University of Western Ontario. Dr. Stiller founded the J. Allyn Taylor International Prize in Medicine, co-founded MaRS, was the Chair of the Ontario Research and Development Challenge Fund Board and was the co-founder of four venture capital funds of over $500 million. He serves on the boards of a number of private and public companies, was founding Chair of Trillium Therapeutics (private company) and was chair of VerioTherapeutics, a Canadian stem cell company that was acquired in 2010 by Fate Corporation, a California - based regeneration company. Together with Robert Klein (the founder of the California Institute of Regenerative Medicine, a state agency responsible for granting approximately $3 billion in stem cell research funding), he co-founded the Cancer Stem Cell Initiative, a Canada-California consortium that has been productive in the search for and identification of cancer stem cells. He serves on the board of Revera Corporation, one of the nation's largest seniors' accommodation, health and long-term care and services companies.

Expand

, Mr. , Luke Beshar ,

Luke Beshar served as Executive Vice President and Chief Financial Officer of NPS Pharmaceuticals from 2007 to 2015. In this role he was responsible for financial management, investor relations, information technology, technical operations, supply-chain management, facilities, project management, contracts & outsourcing and stategic and alliance management. Mr. Beshar has utilized his 30 years of experience and strategic and financial expertise to help transform NPS into a global biopharmaceutical company that is bringing innovative therapies to patients with rare diseases around the world. Under his financial leadership, NPS secured approximately $400 million of capital and its market capitalization increased from $180 million to more than $3 billion. Prior to joining NPS, Mr. Beshar served as Executive Vice President and Chief Financial Officer of Cambrex Corporation, a global life sciences company. At Cambrex, his accomplishments included raising approximately $600 million of new capital, building a high performance global finance team, and leading a process of evaluating strategic alernatives, which resulted in the sale of non-strategic operations for $460 million and an $11 per share special dividend to shareholders. Mr. Beshar began his career with Arthur Andersen & Co. and is a certified public accountant. He obtained his bachelor's degree in Accounting and Finance from Michigan State University and is a graduate of The Executive Program at the Darden Graduate School of Business at the University of Virgina.

Expand

, Dr. , Henry Friesen ,

Dr. Friesen, was the President of the Canadian Government's Medical Research Council, and the architect and lead champion for the creation the Canadian Institutes for Health Research, President of the National Cancer Institute of Canada and President of the Canadian Society for Clinical Investigation. He is the Past Founding Chair of Genome Canada. A Fellow of the Royal Society of Canada, Dr. Friesen was named a Companion of the Order of Canada and was inducted into the Canadian Medical Hall of Fame and the Order of Manitoba. He was also awarded the Gairdner Foundation Wightman Award; the McLaughlin Medal of the Royal Society of Canada; and the Koch Medal: the highest award of the Endocrine Society. He was presented with the Frederic Newton Gisborne Starr Award by the Canadian Medical Association, the association's highest award, in 2006. Dr. Friesen also holds eight Honorary Doctorates from Canadian universities.

Expand

, Dr. , Robert L. Kirkman ,

Dr. Kirkman served as President and Chief Executive Officer of Oncothyreon from September 2006 until his retirement in January 2016. From 2005 to 2006, he was acting President and Chief Executive Officer of Xcyte Therapies, which concluded a merger with Cyclacel Pharmaceuticals, both development-stage biopharmaceutical companies, in March of 2006. From 2004 to 2005, Dr. Kirkman was Chief Business Officer and Vice President of Xcyte. From 1998 to 2003, Dr. Kirkman was Vice President, Business Development and Corporate Communications of Protein Design Labs, a biopharmaceutical company. Dr. Kirkman holds a M.D. degree from Harvard Medical School and a B.A. in economics from Yale University.

Expand

, Dr. , Michael Moore ,

Dr. Moore was the Founder Chair of MISSION Therapeutics Limited, a UK drug discovery company targeting deubiquitinating enzymes for multiple disease indications. He also holds non-executive positions with UK biopharmaceutical companies including PsiOxus Therapeutics Limited, of which he was Founding Chairman, and Chronos Therapeutics Limited. From 2004-2013, Dr. Moore was non-executive Chair of Trillium Therapeutics Inc. (private) and from 2003-2008 Chief Executive Officer of Plramed Limited, a UK-based biotechnology company targeting the PI 3-kinase superfamily, which was acquired by Roche in 2008. Prior to Plramed, Dr. Moore held progressive positions at Xenova Group plc (1988-2003), including Research Director and Chief Scientific Officer. Dr. Moore’s academic career included a tenured appointment at the Paterson Institute for Cancer Research (1980) and the University of Manchester Medical School where he was Honorary Reader in immunology and oncology (1986). Dr. Moore received Ph.D. and D.Sc. degrees from the University of Nottingham (a member of the Russell Group).

Expand

, Dr. , Thomas Reynolds ,

Dr. Thomas Reynolds served as Chief Medical Officer of Seattle Genetics from March 2007 until his retirement in February 2013. While at Seattle Genetics, he was responsible for building and leading an integrated clinical development, regulatory and medical affairs organization, highlighted by the development and approval of ADCETRIS. From 2002 to 2007, Dr. Reynolds served at ZymoGenetics (acquired by Bristol-Myers Squibb in 2010), most recently as Vice President, Medical Affairs, where he oversaw the clinical development and regulatory filing of RECOTHROM. Previously, he was Vice President, Clinical Affairs at Targeted Genetics, and before that he was at Somatix Therapy (acquired by Cell Genesys in 1997). Dr. Reynolds received his M.D. and Ph.D. in Biophysics from Stanford University and a B.A. in Chemistry from Dartmouth College.

Expand

, Dr. , Niclas Stiernholm ,

Dr. Stiernholm's primary responsibilities include overseeing the company's strategic direction, executing business development plans and ensuring that our scientific programs are properly funded and advance according to schedule. Dr. Stiernholm became our President and Chief Executive Officer on our merger with the private company Trillium Therapeutics in April 2013. He joined Trillium from YM BioSciences where he was Executive Vice President and Chief Scientific Officer. While there, he played a significant role in the success of their Initial Public Offering (IPO) in 2002. Dr. Stiernholm began his industry career as a member of Allelix Biopharmaceuticals' business development office. He currently serves on the boards of AvidBiologics and Vasomune Therapeutics. He received his Ph.D. in immunology from the University of Toronto, where he also completed his postdoctoral training.

Expand

, Dr. , Helen Tayton-Martin ,

Dr. Tayton-Martin, Chief Business Officer at Adaptimmune, has over 25 years of experience working within the pharma, biotech and consulting environment in disciplines across preclinical and clinical development, outsourcing, strategic planning, due diligence and business development. She co-founded Adaptimmune from the former company, Avidex Limited, where she had been responsible for commercial development of the soluble TCR program in cancer and HIV therapy from 2005 to 2008. Dr. Tayton-Martin transitioned to become Adaptimmune's Chief Business Officer in March 2017, having served as its Chief Operating Officer since 2008, a role in which she oversaw the transition of all operations in the company from 5 to 300 staff, through transatlantic growth, multiple clinical, academic and commercial collaborations and private and public financing through to its NASDAQ IPO.

Expand
More > More > More >

Recent Presentations

Thumb Date Download
Nov 18, 2017 SNO 2017 Abstract 4329 684 KB
Sep 26, 2017 Q3 2017 Corporate Presentation 2.87 MB
Jun 05, 2017 2017 ASCO Annual Meeting 415 KB
Apr 03, 2017 AACR 2017 Abstract #2646 9.96 MB
Apr 03, 2017 AACR 2017 Abstract #2653 720 KB

EMAIL ALERTS

Email Address: *
First Name:
Mailing Lists




 
Enter the code shown above.

Powered By Q4 Inc. 5.2.0.9